Russell Investments Group
TSHA icon

Russell Investments Group’s Taysha Gene Therapies TSHA Stock Holding History

Russell Investments Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420K Buy
61,705
+44,776
+264% +$265K ﹤0.01% 2860
2026
Q1 		$75.7K Hold
16,929
– – ﹤0.01% 3173
2025
Q4 		$93.1K Sell
16,929
-1,236
-7% -$6K ﹤0.01% 3069
2025
Q3 		$59.4K Buy
+18,165
New +$51.4K ﹤0.01% 3210

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Russell Investments Group's TSHA Position: Q2 2026 in Review

Russell Investments Group increased its Taysha Gene Therapies (TSHA) stake by 264% in Q2 2026, buying an estimated $265K and bringing the position to 61,705 shares worth $420K. The position accounts for ﹤0.01% of the portfolio, ranked #2860.

Russell Investments Group first reported a position in TSHA in Q3 2025 and has held it in 4 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Russell Investments Group held 61,705 shares of Taysha Gene Therapies worth $420K as of Q2 2026.
  • Russell Investments Group bought 44,776 Taysha Gene Therapies shares in Q2 2026, an estimated $265K.
  • Taysha Gene Therapies made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2860 holding.
  • Russell Investments Group first reported a position in Taysha Gene Therapies in Q3 2025 and has held it in 4 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.